Global Psoriatic Arthritis Drugs Market Growth 2025-2031
The global Psoriatic Arthritis Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Psoriatic Arthritis Drugs Industry Forecast” looks at past sales and reviews total world Psoriatic Arthritis Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Psoriatic Arthritis Drugs sales for 2025 through 2031. With Psoriatic Arthritis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psoriatic Arthritis Drugs industry.
This Insight Report provides a comprehensive analysis of the global Psoriatic Arthritis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psoriatic Arthritis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psoriatic Arthritis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psoriatic Arthritis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psoriatic Arthritis Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Psoriatic Arthritis Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Psoriatic Arthritis Drugs market?
What factors are driving Psoriatic Arthritis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psoriatic Arthritis Drugs market opportunities vary by end market size?
How does Psoriatic Arthritis Drugs break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Psoriatic Arthritis Drugs Industry Forecast” looks at past sales and reviews total world Psoriatic Arthritis Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Psoriatic Arthritis Drugs sales for 2025 through 2031. With Psoriatic Arthritis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psoriatic Arthritis Drugs industry.
This Insight Report provides a comprehensive analysis of the global Psoriatic Arthritis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psoriatic Arthritis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psoriatic Arthritis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psoriatic Arthritis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psoriatic Arthritis Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Psoriatic Arthritis Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
- Other
- Mild Psoriatic Arthritis
- Moderate Psoriatic Arthritis
- Severe Psoriatic Arthritis
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Abbvie
- Janssen
- Amgen
- Pfizer
- Eli-Lilly
- Celgene
What is the 10-year outlook for the global Psoriatic Arthritis Drugs market?
What factors are driving Psoriatic Arthritis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psoriatic Arthritis Drugs market opportunities vary by end market size?
How does Psoriatic Arthritis Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antidiabetic Thiazolidinediones Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antidiabetic Thiazolidinediones by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antidiabetic Thiazolidinediones by Country/Region, 2020, 2024 & 2031
2.2 Antidiabetic Thiazolidinediones Segment by Type
2.2.1 Rosiglitazone
2.2.2 Pioglitazone
2.3 Antidiabetic Thiazolidinediones Sales by Type
2.3.1 Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2020-2025)
2.3.2 Global Antidiabetic Thiazolidinediones Revenue and Market Share by Type (2020-2025)
2.3.3 Global Antidiabetic Thiazolidinediones Sale Price by Type (2020-2025)
2.4 Antidiabetic Thiazolidinediones Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Antidiabetic Thiazolidinediones Sales by Application
2.5.1 Global Antidiabetic Thiazolidinediones Sale Market Share by Application (2020-2025)
2.5.2 Global Antidiabetic Thiazolidinediones Revenue and Market Share by Application (2020-2025)
2.5.3 Global Antidiabetic Thiazolidinediones Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Antidiabetic Thiazolidinediones Breakdown Data by Company
3.1.1 Global Antidiabetic Thiazolidinediones Annual Sales by Company (2020-2025)
3.1.2 Global Antidiabetic Thiazolidinediones Sales Market Share by Company (2020-2025)
3.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Company (2020-2025)
3.2.1 Global Antidiabetic Thiazolidinediones Revenue by Company (2020-2025)
3.2.2 Global Antidiabetic Thiazolidinediones Revenue Market Share by Company (2020-2025)
3.3 Global Antidiabetic Thiazolidinediones Sale Price by Company
3.4 Key Manufacturers Antidiabetic Thiazolidinediones Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antidiabetic Thiazolidinediones Product Location Distribution
3.4.2 Players Antidiabetic Thiazolidinediones Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIDIABETIC THIAZOLIDINEDIONES BY GEOGRAPHIC REGION
4.1 World Historic Antidiabetic Thiazolidinediones Market Size by Geographic Region (2020-2025)
4.1.1 Global Antidiabetic Thiazolidinediones Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antidiabetic Thiazolidinediones Market Size by Country/Region (2020-2025)
4.2.1 Global Antidiabetic Thiazolidinediones Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antidiabetic Thiazolidinediones Sales Growth
4.4 APAC Antidiabetic Thiazolidinediones Sales Growth
4.5 Europe Antidiabetic Thiazolidinediones Sales Growth
4.6 Middle East & Africa Antidiabetic Thiazolidinediones Sales Growth
5 AMERICAS
5.1 Americas Antidiabetic Thiazolidinediones Sales by Country
5.1.1 Americas Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
5.1.2 Americas Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
5.2 Americas Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
5.3 Americas Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antidiabetic Thiazolidinediones Sales by Region
6.1.1 APAC Antidiabetic Thiazolidinediones Sales by Region (2020-2025)
6.1.2 APAC Antidiabetic Thiazolidinediones Revenue by Region (2020-2025)
6.2 APAC Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
6.3 APAC Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antidiabetic Thiazolidinediones by Country
7.1.1 Europe Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
7.1.2 Europe Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
7.2 Europe Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
7.3 Europe Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antidiabetic Thiazolidinediones by Country
8.1.1 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
8.2 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
8.3 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antidiabetic Thiazolidinediones
10.3 Manufacturing Process Analysis of Antidiabetic Thiazolidinediones
10.4 Industry Chain Structure of Antidiabetic Thiazolidinediones
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antidiabetic Thiazolidinediones Distributors
11.3 Antidiabetic Thiazolidinediones Customer
12 WORLD FORECAST REVIEW FOR ANTIDIABETIC THIAZOLIDINEDIONES BY GEOGRAPHIC REGION
12.1 Global Antidiabetic Thiazolidinediones Market Size Forecast by Region
12.1.1 Global Antidiabetic Thiazolidinediones Forecast by Region (2026-2031)
12.1.2 Global Antidiabetic Thiazolidinediones Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antidiabetic Thiazolidinediones Forecast by Type (2026-2031)
12.7 Global Antidiabetic Thiazolidinediones Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Takeda Pharmaceuticals
13.2.1 Takeda Pharmaceuticals Company Information
13.2.2 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Takeda Pharmaceuticals Main Business Overview
13.2.5 Takeda Pharmaceuticals Latest Developments
13.3 Eli Lilly
13.3.1 Eli Lilly Company Information
13.3.2 Eli Lilly Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Eli Lilly Main Business Overview
13.3.5 Eli Lilly Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 Novo Nordisk
13.5.1 Novo Nordisk Company Information
13.5.2 Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Novo Nordisk Main Business Overview
13.5.5 Novo Nordisk Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.7.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Boehringer Ingelheim
13.10.1 Boehringer Ingelheim Company Information
13.10.2 Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Boehringer Ingelheim Main Business Overview
13.10.5 Boehringer Ingelheim Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antidiabetic Thiazolidinediones Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antidiabetic Thiazolidinediones by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antidiabetic Thiazolidinediones by Country/Region, 2020, 2024 & 2031
2.2 Antidiabetic Thiazolidinediones Segment by Type
2.2.1 Rosiglitazone
2.2.2 Pioglitazone
2.3 Antidiabetic Thiazolidinediones Sales by Type
2.3.1 Global Antidiabetic Thiazolidinediones Sales Market Share by Type (2020-2025)
2.3.2 Global Antidiabetic Thiazolidinediones Revenue and Market Share by Type (2020-2025)
2.3.3 Global Antidiabetic Thiazolidinediones Sale Price by Type (2020-2025)
2.4 Antidiabetic Thiazolidinediones Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Antidiabetic Thiazolidinediones Sales by Application
2.5.1 Global Antidiabetic Thiazolidinediones Sale Market Share by Application (2020-2025)
2.5.2 Global Antidiabetic Thiazolidinediones Revenue and Market Share by Application (2020-2025)
2.5.3 Global Antidiabetic Thiazolidinediones Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Antidiabetic Thiazolidinediones Breakdown Data by Company
3.1.1 Global Antidiabetic Thiazolidinediones Annual Sales by Company (2020-2025)
3.1.2 Global Antidiabetic Thiazolidinediones Sales Market Share by Company (2020-2025)
3.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Company (2020-2025)
3.2.1 Global Antidiabetic Thiazolidinediones Revenue by Company (2020-2025)
3.2.2 Global Antidiabetic Thiazolidinediones Revenue Market Share by Company (2020-2025)
3.3 Global Antidiabetic Thiazolidinediones Sale Price by Company
3.4 Key Manufacturers Antidiabetic Thiazolidinediones Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antidiabetic Thiazolidinediones Product Location Distribution
3.4.2 Players Antidiabetic Thiazolidinediones Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTIDIABETIC THIAZOLIDINEDIONES BY GEOGRAPHIC REGION
4.1 World Historic Antidiabetic Thiazolidinediones Market Size by Geographic Region (2020-2025)
4.1.1 Global Antidiabetic Thiazolidinediones Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antidiabetic Thiazolidinediones Market Size by Country/Region (2020-2025)
4.2.1 Global Antidiabetic Thiazolidinediones Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antidiabetic Thiazolidinediones Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antidiabetic Thiazolidinediones Sales Growth
4.4 APAC Antidiabetic Thiazolidinediones Sales Growth
4.5 Europe Antidiabetic Thiazolidinediones Sales Growth
4.6 Middle East & Africa Antidiabetic Thiazolidinediones Sales Growth
5 AMERICAS
5.1 Americas Antidiabetic Thiazolidinediones Sales by Country
5.1.1 Americas Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
5.1.2 Americas Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
5.2 Americas Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
5.3 Americas Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antidiabetic Thiazolidinediones Sales by Region
6.1.1 APAC Antidiabetic Thiazolidinediones Sales by Region (2020-2025)
6.1.2 APAC Antidiabetic Thiazolidinediones Revenue by Region (2020-2025)
6.2 APAC Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
6.3 APAC Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antidiabetic Thiazolidinediones by Country
7.1.1 Europe Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
7.1.2 Europe Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
7.2 Europe Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
7.3 Europe Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antidiabetic Thiazolidinediones by Country
8.1.1 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antidiabetic Thiazolidinediones Revenue by Country (2020-2025)
8.2 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Type (2020-2025)
8.3 Middle East & Africa Antidiabetic Thiazolidinediones Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antidiabetic Thiazolidinediones
10.3 Manufacturing Process Analysis of Antidiabetic Thiazolidinediones
10.4 Industry Chain Structure of Antidiabetic Thiazolidinediones
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antidiabetic Thiazolidinediones Distributors
11.3 Antidiabetic Thiazolidinediones Customer
12 WORLD FORECAST REVIEW FOR ANTIDIABETIC THIAZOLIDINEDIONES BY GEOGRAPHIC REGION
12.1 Global Antidiabetic Thiazolidinediones Market Size Forecast by Region
12.1.1 Global Antidiabetic Thiazolidinediones Forecast by Region (2026-2031)
12.1.2 Global Antidiabetic Thiazolidinediones Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antidiabetic Thiazolidinediones Forecast by Type (2026-2031)
12.7 Global Antidiabetic Thiazolidinediones Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.1.3 Sanofi Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Takeda Pharmaceuticals
13.2.1 Takeda Pharmaceuticals Company Information
13.2.2 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Takeda Pharmaceuticals Main Business Overview
13.2.5 Takeda Pharmaceuticals Latest Developments
13.3 Eli Lilly
13.3.1 Eli Lilly Company Information
13.3.2 Eli Lilly Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.3.3 Eli Lilly Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Eli Lilly Main Business Overview
13.3.5 Eli Lilly Latest Developments
13.4 Merck & Co.
13.4.1 Merck & Co. Company Information
13.4.2 Merck & Co. Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.4.3 Merck & Co. Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck & Co. Main Business Overview
13.4.5 Merck & Co. Latest Developments
13.5 Novo Nordisk
13.5.1 Novo Nordisk Company Information
13.5.2 Novo Nordisk Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Novo Nordisk Main Business Overview
13.5.5 Novo Nordisk Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.7.3 Pfizer Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.8.3 AstraZeneca Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Boehringer Ingelheim
13.10.1 Boehringer Ingelheim Company Information
13.10.2 Boehringer Ingelheim Antidiabetic Thiazolidinediones Product Portfolios and Specifications
13.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Boehringer Ingelheim Main Business Overview
13.10.5 Boehringer Ingelheim Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Psoriatic Arthritis Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Psoriatic Arthritis Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of TNF Inhibitors
Table 4. Major Players of PDE4 Inhibitors
Table 5. Major Players of Interleukin Blockers
Table 6. Major Players of Other
Table 7. Global Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 8. Global Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Table 9. Global Psoriatic Arthritis Drugs Revenue by Type (2020-2025) & ($ million)
Table 10. Global Psoriatic Arthritis Drugs Revenue Market Share by Type (2020-2025)
Table 11. Global Psoriatic Arthritis Drugs Sale Price by Type (2020-2025) & (USD/MT)
Table 12. Global Psoriatic Arthritis Drugs Sale by Application (2020-2025) & (K MT)
Table 13. Global Psoriatic Arthritis Drugs Sale Market Share by Application (2020-2025)
Table 14. Global Psoriatic Arthritis Drugs Revenue by Application (2020-2025) & ($ million)
Table 15. Global Psoriatic Arthritis Drugs Revenue Market Share by Application (2020-2025)
Table 16. Global Psoriatic Arthritis Drugs Sale Price by Application (2020-2025) & (USD/MT)
Table 17. Global Psoriatic Arthritis Drugs Sales by Company (2020-2025) & (K MT)
Table 18. Global Psoriatic Arthritis Drugs Sales Market Share by Company (2020-2025)
Table 19. Global Psoriatic Arthritis Drugs Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Psoriatic Arthritis Drugs Revenue Market Share by Company (2020-2025)
Table 21. Global Psoriatic Arthritis Drugs Sale Price by Company (2020-2025) & (USD/MT)
Table 22. Key Manufacturers Psoriatic Arthritis Drugs Producing Area Distribution and Sales Area
Table 23. Players Psoriatic Arthritis Drugs Products Offered
Table 24. Psoriatic Arthritis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Psoriatic Arthritis Drugs Sales by Geographic Region (2020-2025) & (K MT)
Table 28. Global Psoriatic Arthritis Drugs Sales Market Share Geographic Region (2020-2025)
Table 29. Global Psoriatic Arthritis Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Psoriatic Arthritis Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Psoriatic Arthritis Drugs Sales by Country/Region (2020-2025) & (K MT)
Table 32. Global Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2020-2025)
Table 33. Global Psoriatic Arthritis Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Psoriatic Arthritis Drugs Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 36. Americas Psoriatic Arthritis Drugs Sales Market Share by Country (2020-2025)
Table 37. Americas Psoriatic Arthritis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 39. Americas Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 40. APAC Psoriatic Arthritis Drugs Sales by Region (2020-2025) & (K MT)
Table 41. APAC Psoriatic Arthritis Drugs Sales Market Share by Region (2020-2025)
Table 42. APAC Psoriatic Arthritis Drugs Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 44. APAC Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 45. Europe Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 46. Europe Psoriatic Arthritis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 48. Europe Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 49. Middle East & Africa Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 50. Middle East & Africa Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 52. Middle East & Africa Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 53. Key Market Drivers & Growth Opportunities of Psoriatic Arthritis Drugs
Table 54. Key Market Challenges & Risks of Psoriatic Arthritis Drugs
Table 55. Key Industry Trends of Psoriatic Arthritis Drugs
Table 56. Psoriatic Arthritis Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Psoriatic Arthritis Drugs Distributors List
Table 59. Psoriatic Arthritis Drugs Customer List
Table 60. Global Psoriatic Arthritis Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 61. Global Psoriatic Arthritis Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 62. Americas Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 63. Americas Psoriatic Arthritis Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 64. APAC Psoriatic Arthritis Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 65. APAC Psoriatic Arthritis Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Europe Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 67. Europe Psoriatic Arthritis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 69. Middle East & Africa Psoriatic Arthritis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Global Psoriatic Arthritis Drugs Sales Forecast by Type (2026-2031) & (K MT)
Table 71. Global Psoriatic Arthritis Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 72. Global Psoriatic Arthritis Drugs Sales Forecast by Application (2026-2031) & (K MT)
Table 73. Global Psoriatic Arthritis Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 74. Abbvie Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Abbvie Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 76. Abbvie Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 77. Abbvie Main Business
Table 78. Abbvie Latest Developments
Table 79. Janssen Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Janssen Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 81. Janssen Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 82. Janssen Main Business
Table 83. Janssen Latest Developments
Table 84. Amgen Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Amgen Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 86. Amgen Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. Amgen Main Business
Table 88. Amgen Latest Developments
Table 89. Pfizer Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 91. Pfizer Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94. Eli-Lilly Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Eli-Lilly Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 96. Eli-Lilly Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 97. Eli-Lilly Main Business
Table 98. Eli-Lilly Latest Developments
Table 99. Celgene Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Celgene Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 101. Celgene Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 102. Celgene Main Business
Table 103. Celgene Latest Developments
Table 1. Psoriatic Arthritis Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Psoriatic Arthritis Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of TNF Inhibitors
Table 4. Major Players of PDE4 Inhibitors
Table 5. Major Players of Interleukin Blockers
Table 6. Major Players of Other
Table 7. Global Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 8. Global Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Table 9. Global Psoriatic Arthritis Drugs Revenue by Type (2020-2025) & ($ million)
Table 10. Global Psoriatic Arthritis Drugs Revenue Market Share by Type (2020-2025)
Table 11. Global Psoriatic Arthritis Drugs Sale Price by Type (2020-2025) & (USD/MT)
Table 12. Global Psoriatic Arthritis Drugs Sale by Application (2020-2025) & (K MT)
Table 13. Global Psoriatic Arthritis Drugs Sale Market Share by Application (2020-2025)
Table 14. Global Psoriatic Arthritis Drugs Revenue by Application (2020-2025) & ($ million)
Table 15. Global Psoriatic Arthritis Drugs Revenue Market Share by Application (2020-2025)
Table 16. Global Psoriatic Arthritis Drugs Sale Price by Application (2020-2025) & (USD/MT)
Table 17. Global Psoriatic Arthritis Drugs Sales by Company (2020-2025) & (K MT)
Table 18. Global Psoriatic Arthritis Drugs Sales Market Share by Company (2020-2025)
Table 19. Global Psoriatic Arthritis Drugs Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Psoriatic Arthritis Drugs Revenue Market Share by Company (2020-2025)
Table 21. Global Psoriatic Arthritis Drugs Sale Price by Company (2020-2025) & (USD/MT)
Table 22. Key Manufacturers Psoriatic Arthritis Drugs Producing Area Distribution and Sales Area
Table 23. Players Psoriatic Arthritis Drugs Products Offered
Table 24. Psoriatic Arthritis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Psoriatic Arthritis Drugs Sales by Geographic Region (2020-2025) & (K MT)
Table 28. Global Psoriatic Arthritis Drugs Sales Market Share Geographic Region (2020-2025)
Table 29. Global Psoriatic Arthritis Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Psoriatic Arthritis Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Psoriatic Arthritis Drugs Sales by Country/Region (2020-2025) & (K MT)
Table 32. Global Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2020-2025)
Table 33. Global Psoriatic Arthritis Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Psoriatic Arthritis Drugs Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 36. Americas Psoriatic Arthritis Drugs Sales Market Share by Country (2020-2025)
Table 37. Americas Psoriatic Arthritis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 39. Americas Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 40. APAC Psoriatic Arthritis Drugs Sales by Region (2020-2025) & (K MT)
Table 41. APAC Psoriatic Arthritis Drugs Sales Market Share by Region (2020-2025)
Table 42. APAC Psoriatic Arthritis Drugs Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 44. APAC Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 45. Europe Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 46. Europe Psoriatic Arthritis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 48. Europe Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 49. Middle East & Africa Psoriatic Arthritis Drugs Sales by Country (2020-2025) & (K MT)
Table 50. Middle East & Africa Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Psoriatic Arthritis Drugs Sales by Type (2020-2025) & (K MT)
Table 52. Middle East & Africa Psoriatic Arthritis Drugs Sales by Application (2020-2025) & (K MT)
Table 53. Key Market Drivers & Growth Opportunities of Psoriatic Arthritis Drugs
Table 54. Key Market Challenges & Risks of Psoriatic Arthritis Drugs
Table 55. Key Industry Trends of Psoriatic Arthritis Drugs
Table 56. Psoriatic Arthritis Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Psoriatic Arthritis Drugs Distributors List
Table 59. Psoriatic Arthritis Drugs Customer List
Table 60. Global Psoriatic Arthritis Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 61. Global Psoriatic Arthritis Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 62. Americas Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 63. Americas Psoriatic Arthritis Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 64. APAC Psoriatic Arthritis Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 65. APAC Psoriatic Arthritis Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Europe Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 67. Europe Psoriatic Arthritis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Psoriatic Arthritis Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 69. Middle East & Africa Psoriatic Arthritis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Global Psoriatic Arthritis Drugs Sales Forecast by Type (2026-2031) & (K MT)
Table 71. Global Psoriatic Arthritis Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 72. Global Psoriatic Arthritis Drugs Sales Forecast by Application (2026-2031) & (K MT)
Table 73. Global Psoriatic Arthritis Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 74. Abbvie Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Abbvie Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 76. Abbvie Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 77. Abbvie Main Business
Table 78. Abbvie Latest Developments
Table 79. Janssen Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Janssen Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 81. Janssen Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 82. Janssen Main Business
Table 83. Janssen Latest Developments
Table 84. Amgen Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Amgen Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 86. Amgen Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. Amgen Main Business
Table 88. Amgen Latest Developments
Table 89. Pfizer Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Pfizer Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 91. Pfizer Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94. Eli-Lilly Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Eli-Lilly Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 96. Eli-Lilly Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 97. Eli-Lilly Main Business
Table 98. Eli-Lilly Latest Developments
Table 99. Celgene Basic Information, Psoriatic Arthritis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Celgene Psoriatic Arthritis Drugs Product Portfolios and Specifications
Table 101. Celgene Psoriatic Arthritis Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 102. Celgene Main Business
Table 103. Celgene Latest Developments
LIST OF FIGURES
Figure 1. Picture of Psoriatic Arthritis Drugs
Figure 2. Psoriatic Arthritis Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psoriatic Arthritis Drugs Sales Growth Rate 2020-2031 (K MT)
Figure 7. Global Psoriatic Arthritis Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Psoriatic Arthritis Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2024)
Figure 10. Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of TNF Inhibitors
Figure 12. Product Picture of PDE4 Inhibitors
Figure 13. Product Picture of Interleukin Blockers
Figure 14. Product Picture of Other
Figure 15. Global Psoriatic Arthritis Drugs Sales Market Share by Type in 2025
Figure 16. Global Psoriatic Arthritis Drugs Revenue Market Share by Type (2020-2025)
Figure 17. Psoriatic Arthritis Drugs Consumed in Mild Psoriatic Arthritis
Figure 18. Global Psoriatic Arthritis Drugs Market: Mild Psoriatic Arthritis (2020-2025) & (K MT)
Figure 19. Psoriatic Arthritis Drugs Consumed in Moderate Psoriatic Arthritis
Figure 20. Global Psoriatic Arthritis Drugs Market: Moderate Psoriatic Arthritis (2020-2025) & (K MT)
Figure 21. Psoriatic Arthritis Drugs Consumed in Severe Psoriatic Arthritis
Figure 22. Global Psoriatic Arthritis Drugs Market: Severe Psoriatic Arthritis (2020-2025) & (K MT)
Figure 23. Global Psoriatic Arthritis Drugs Sale Market Share by Application (2024)
Figure 24. Global Psoriatic Arthritis Drugs Revenue Market Share by Application in 2025
Figure 25. Psoriatic Arthritis Drugs Sales by Company in 2025 (K MT)
Figure 26. Global Psoriatic Arthritis Drugs Sales Market Share by Company in 2025
Figure 27. Psoriatic Arthritis Drugs Revenue by Company in 2025 ($ millions)
Figure 28. Global Psoriatic Arthritis Drugs Revenue Market Share by Company in 2025
Figure 29. Global Psoriatic Arthritis Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Psoriatic Arthritis Drugs Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 32. Americas Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 33. APAC Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 34. APAC Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 35. Europe Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 36. Europe Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 38. Middle East & Africa Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 39. Americas Psoriatic Arthritis Drugs Sales Market Share by Country in 2025
Figure 40. Americas Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Figure 41. Americas Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 42. Americas Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 43. United States Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Psoriatic Arthritis Drugs Sales Market Share by Region in 2025
Figure 48. APAC Psoriatic Arthritis Drugs Revenue Market Share by Region (2020-2025)
Figure 49. APAC Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 50. APAC Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 51. China Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. India Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Psoriatic Arthritis Drugs Sales Market Share by Country in 2025
Figure 59. Europe Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Figure 60. Europe Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 61. Europe Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 62. Germany Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. France Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 70. Egypt Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Psoriatic Arthritis Drugs in 2025
Figure 76. Manufacturing Process Analysis of Psoriatic Arthritis Drugs
Figure 77. Industry Chain Structure of Psoriatic Arthritis Drugs
Figure 78. Channels of Distribution
Figure 79. Global Psoriatic Arthritis Drugs Sales Market Forecast by Region (2026-2031)
Figure 80. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Psoriatic Arthritis Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Psoriatic Arthritis Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Psoriatic Arthritis Drugs
Figure 2. Psoriatic Arthritis Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psoriatic Arthritis Drugs Sales Growth Rate 2020-2031 (K MT)
Figure 7. Global Psoriatic Arthritis Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Psoriatic Arthritis Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2024)
Figure 10. Psoriatic Arthritis Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of TNF Inhibitors
Figure 12. Product Picture of PDE4 Inhibitors
Figure 13. Product Picture of Interleukin Blockers
Figure 14. Product Picture of Other
Figure 15. Global Psoriatic Arthritis Drugs Sales Market Share by Type in 2025
Figure 16. Global Psoriatic Arthritis Drugs Revenue Market Share by Type (2020-2025)
Figure 17. Psoriatic Arthritis Drugs Consumed in Mild Psoriatic Arthritis
Figure 18. Global Psoriatic Arthritis Drugs Market: Mild Psoriatic Arthritis (2020-2025) & (K MT)
Figure 19. Psoriatic Arthritis Drugs Consumed in Moderate Psoriatic Arthritis
Figure 20. Global Psoriatic Arthritis Drugs Market: Moderate Psoriatic Arthritis (2020-2025) & (K MT)
Figure 21. Psoriatic Arthritis Drugs Consumed in Severe Psoriatic Arthritis
Figure 22. Global Psoriatic Arthritis Drugs Market: Severe Psoriatic Arthritis (2020-2025) & (K MT)
Figure 23. Global Psoriatic Arthritis Drugs Sale Market Share by Application (2024)
Figure 24. Global Psoriatic Arthritis Drugs Revenue Market Share by Application in 2025
Figure 25. Psoriatic Arthritis Drugs Sales by Company in 2025 (K MT)
Figure 26. Global Psoriatic Arthritis Drugs Sales Market Share by Company in 2025
Figure 27. Psoriatic Arthritis Drugs Revenue by Company in 2025 ($ millions)
Figure 28. Global Psoriatic Arthritis Drugs Revenue Market Share by Company in 2025
Figure 29. Global Psoriatic Arthritis Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Psoriatic Arthritis Drugs Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 32. Americas Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 33. APAC Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 34. APAC Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 35. Europe Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 36. Europe Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Psoriatic Arthritis Drugs Sales 2020-2025 (K MT)
Figure 38. Middle East & Africa Psoriatic Arthritis Drugs Revenue 2020-2025 ($ millions)
Figure 39. Americas Psoriatic Arthritis Drugs Sales Market Share by Country in 2025
Figure 40. Americas Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Figure 41. Americas Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 42. Americas Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 43. United States Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Psoriatic Arthritis Drugs Sales Market Share by Region in 2025
Figure 48. APAC Psoriatic Arthritis Drugs Revenue Market Share by Region (2020-2025)
Figure 49. APAC Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 50. APAC Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 51. China Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. India Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Psoriatic Arthritis Drugs Sales Market Share by Country in 2025
Figure 59. Europe Psoriatic Arthritis Drugs Revenue Market Share by Country (2020-2025)
Figure 60. Europe Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 61. Europe Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 62. Germany Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. France Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Psoriatic Arthritis Drugs Sales Market Share by Application (2020-2025)
Figure 70. Egypt Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Psoriatic Arthritis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Psoriatic Arthritis Drugs in 2025
Figure 76. Manufacturing Process Analysis of Psoriatic Arthritis Drugs
Figure 77. Industry Chain Structure of Psoriatic Arthritis Drugs
Figure 78. Channels of Distribution
Figure 79. Global Psoriatic Arthritis Drugs Sales Market Forecast by Region (2026-2031)
Figure 80. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Psoriatic Arthritis Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Psoriatic Arthritis Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Psoriatic Arthritis Drugs Revenue Market Share Forecast by Application (2026-2031)
